Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECTS OF BUPRENORPHINE AND NALOXONE IN MORPHINE-STABILIZED OPIOID ADDICTS
Autore:
FUDALA PJ; YU E; MACFADDEN W; BOARDMAN C;
Indirizzi:
UNIV PENN,SCH MED,DEPT PSYCHIAT,DEPT VET AFFAIRS MED CTR,BLDG 15,UNIV& WOODLAND AVE PHILADELPHIA PA 19104 CHILDRENS HOSP PHILADELPHIA PHILADELPHIA PA 19104 NIDA,MEDICAT DEV DIV ROCKVILLE MD 00000
Titolo Testata:
Drug and alcohol dependence
fascicolo: 1, volume: 50, anno: 1998,
pagine: 1 - 8
SICI:
0376-8716(1998)50:1<1:EOBANI>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
METHADONE-MAINTAINED VOLUNTEERS; ACUTE PHYSICAL-DEPENDENCE; PRECIPITATED WITHDRAWAL; HUMANS; MAINTENANCE; EXPOSURE; ABUSE;
Keywords:
BUPRENORPHINE; NALOXONE; OPIOID-DEPENDENCE; TREATMENT;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
36
Recensione:
Indirizzi per estratti:
Citazione:
P.J. Fudala et al., "EFFECTS OF BUPRENORPHINE AND NALOXONE IN MORPHINE-STABILIZED OPIOID ADDICTS", Drug and alcohol dependence, 50(1), 1998, pp. 1-8

Abstract

The present study, conducted as part of the development of a buprenorphine/naloxone combination product, was designed to evaluate the individual and combined effects of intravenously administered buprenorphineand naloxone. This in-patient trial used a randomized, double-blind: crossover design. Ten opioid-dependent male subjects were stabilized and maintained on morphine, lj mg given intramuscularly four times daily. Then, at 48- to 72-h intervals, subjects received one of the following by intravenous injection: (1) placebo, (2) morphine 15 mg, (3) buprenorphine 2 mg, (4) buprenorphine 2 mg/naloxone 0.5 mg, and (5) naloxone 0.5 mg. Both naloxone and buprenorphine/naloxone produced significant (P < 0.005) opioid withdrawal effects compared to placebo as assessed with the CINA scale, an instrument which utilizes subject-and observer-reported, as well as physiological parameters. The combination ofbuprenorphine with naloxone in a 4:1 ratio produced opioid antagonist-like effects which should limit its potential for intravenous abuse by opioid addicts. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/04/20 alle ore 00:06:36